Showing results (1011-1020 of 1,842) with videos related to

Sort By:
Pageof 185
ESMO Open|November 13, 2020
Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumoursMaximilian J Mair, Sahra Pajenda, Aysegül Ilhan-Mutlu, et al.
ESMO Open|September 7, 2020
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapiesShani Paluch-Shimon, Nathan I Cherny, Elisabeth G E de Vries, et al.
ESMO Open|November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trialsAndrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
ESMO Open|November 14, 2020
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinomaSahra Ali, Jorge Camarero, Paulavan Hennik, et al.
ESMO Open|November 17, 2020
Lower risk of severe checkpoint inhibitor toxicity in more advanced diseaseRik J Verheijden, Anne M May, Christian U Blank, et al.
ESMO Open|February 15, 2020
Highlights in lung cancer in 2019Kok Haw Jonathan Lim, Sanjay Popat
ESMO Open|March 6, 2020
Genomic-guided precision therapy for soft tissue sarcomaHsing-Wu Chen, Tom Wei-Wu Chen
ESMO Open|March 11, 2020
New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)Angelika M Starzer, Anna S Berghoff
ESMO Open|February 22, 2020
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised studyDavid Lau, Eleftheria Kalaitzaki, David N Church, et al.
ESMO Open|November 2, 2019
Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre studyNatalia Dengina, Timur Mitin, Sergey Gamayunov, et al.
Pageof 185